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Lääkkeenluovutuslaitteet ovat pieniä implantoitavia laitteita, jotka luovuttavat tasaisesti 
lääkeainetta ennalta määrätyn ajan verran. Lääkkeenluovutuslaitteisiin liittyy lukuisia 
hyötyjä verrattuna perinteisiin tapoihin, joihin kuuluu lääkeaineen ottaminen annoksena. 
Perinteisiin tapoihin, kuten suun kautta otettaviin pillereihin liittyy puolestaan useita 
haittapuolia. Lääkkeenluovutuslaitteilla pystytään lisäämään turvallisuutta ja tehokkuut-
ta samalla kun potilaan vaste terapeuttiseen aineeseen paranee. Lisäksi sivuvaikutukset 
pystytään minimoimaan, kun laite on sijoitettu sille spesifiin paikkaan kehossa. Markki-
noilla on ollut jo jonkin aikaa implantoitavia lääkettä vapauttavia laitteita, mutta ne ovat 
olleet suurimmaksi osaksi biohajoamattomia, jolloin kirurginen toimenpide tarvitaan 
niiden poistamiseksi. Biohajoaville implanteille, jotka poistuvat elimistöstä luonnollisia 
aineenvaihdunnan reittejä, olisi selkeäsi kysyntää. 
Lääkkeenluovutuslaitteita on olemassa useita erilaisia, mutta tässä työssä keskityt-
tiin matrix-tyyppisiin laitteisiin, joissa lääkeaine on tasaisesti jakautuneena biohajoa-
vaan polymeerimatriisiin. Kokeellista osuutta varten valittiin kaksi erilaista lääkeainetta: 
askorbiinihapon suola ja deksametasoni. Polymeerit polymeroitiin laktidista ja kapro-
laktonista etyleeni glykolin  (PEG) ollessa ko-initiaattorina. PEG jää polymeroinnissa 
ketjun keskelle. Kaupallista kaprolaktonin ja L-laktidin P(CL-LA) polymeeriä käytettiin 
vertailukohtana. Lisäksi koesarjat tehtiin huokoiselle ja huokoistamattomille näytteille. 
Karakterisointiin käytettiin menetelminä, differentaalista pyyhkäisykalorimetriä, 
termogravimetrista analyysia, geelipermeaatiokromatokrafia, kapillaariviskometriä sekä 
mikro-tietokonetomografia. Lääkeaineiden vapautumista seurattiin UV/VIS-
spektrometrillä. 
Lääkkeen vapautumiseen huomattiin vaikuttavan moni eri tekijä. PEG:n lisääminen 
polymeeriketjun keskelle lisäsi yleisesti lääkeaineen vapautumista. Valittu laktidin 
tyyppi vaikutti myös vapautumiseen. Lääkeaineen konsentaariolla ei havaittu olevan 
suurta vaikutusta vapautumisen profiiliin, mutta kinetiikkaan pystytään vaikuttamaan. 
Ylikriittisellä hiilidioksidilla prosessointi lisäsi yleisesti lääkeaineen vapautumista. Itse 
lääkeaine kuitenkin oli hyvin suuri tekijä lääkkeen vapautumisen kannalta. Askor-
biinihapon johdannaisella oli heikko vuorovaikutus kaikkiin matriisipolymeereihin. Va-
pautuminen oli suhteellisen nopeaa useimmissa tapauksissa. Deksametasonin tapaukses-
sa vapautuminen oli hyvin lähellä nollannen kertaluvun vapautumista. Näillä materiaa-
leilla on selvästi potentiaalia lääkkeenluovutussovelluksiin. Enemmän karakterisointia 
sekä materiaalin hajoamiskoesarja olisi suositeltavaa tehdä, jotta lääkkeenvapautumisen 
käyttäytymistä voisi ymmärtää paremmin. 
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ABSTRACT 
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KYHKYNEN, ANNA-KAISA: Controlled drug delivery from porous lactide-
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Major: Biomaterials 
Examiner: Professor Minna Kellomäki, D. Sc. Niina Ahola 
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Drug delivery devices (DDDs) are small implantable devices making sustained release 
of drug possible over defined time period. DDDs have numerous advantages compared 
to conventional ways of dosing drugs. Traditional ways like oral pills have numerous 
disadvantages. More safety and efficacy methods are needed while better patient com-
pliance is achieved. At the same time, unwanted side effects can be minimized while 
drug is targeted into specific site with minimal released concentration. So far, mostly 
nondegradable DDDs have been available. Their major drawback is that they need re-
moval after the drug is released. There is a need for biodegradable implants that are me-
tabolised from body after DDD has performed needed actions. 
There are many kinds of DDDs, but this thesis concentrated in matrix type biode-
gradable DDDs, where drug is homogenously dispersed in a matrix polymer. For study, 
two very different drugs were chosen: ascorbic acid salt and dexamethasone. Polymers 
were prepared by polymerizing lactide and caprolactone in presence of ethylene glycol 
as co-initiator. Block structure was formed where PEG was left in middle of polymer 
chain. Commercial copolymer of caprolactone and lactide, P(CL-LA) was used as com-
parative polymer. Drug release test series was done to both, porous and nonporous sam-
ples. Characterization was done by using techniques like differential scanning calorime-
try, thermogravimetric analysis, size-exclusion chromatography, capillaryviscometry 
and microcomputed tomography. Drug release was monitored using ultraviolet/visible-
spectrophotometer.  
Many different factors were observed to have an effect on the drug release. In gen-
eral PEG incorporation into backbone increased release rates. Also, type of lactide had 
effect to on the release. Content of drugs was not observed to have much effect on the 
release profile in general, but it was possible to tailor release rates. Processing samples 
with super critical CO2 increased release rates of all samples. Most of all, properties of 
drugs affected in great extent to release kinetics and release profiles of drug-polymer 
combinations. AAs had relatively weak interaction with matrix polymers. Release was 
very fast in most of cases and standard deviations were relatively high in every meas-
urement. For dexamethasone, sustained nearly zero-order kinetics was possible to 
achieve for some materials.  
These materials clearly have great potential in drug release applications in future. 
More material characterization and degradation study could be useful to do for better 
understanding of behavior of used drug-polymer combinations. 
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 ABBREVIATIONS AND EXPLANATIONS 
 
AAs Ascorbic acid salt 
Biodegradation Loss of molecular weight 
Bioerosion Mass loss of polymer 
DEX Dexamethasone 
i.v. Inherent viscosity 
microCT Microcomputed tomography 
Mn Number average molecular mass 
Mw Weight average molecular mass 
sCO2 supercritical carbondioxide 
SEC Size exclusion-cromatography 
Tg Glass transition temperature 
Tm Melting temperature 
PCL poly(ɛ-caprolactone) 
P(CL-LA) Poly(caprolactone-co-lactide) 
PEG Poly(ethylene glycol) 
PEG-b-P(CL-LA) Poly(ethylene glycol)-block-poly(caprolactone-co-lactide) 
PLA Poly(lactide) 
 
 
 
 1 
THEORY PART 
 
 2 
1 INTRODUCTION 
 
Purpose of the work was to study drug release behavior of lactide-based porous biode-
gradable materials and characterization of them using different methods.  
The theory part briefly introduces the principles of controlled drug delivery, possible 
mechanisms of release from biodegradable materials, factors affecting the release kinet-
ics and degradation and drug release from porous materials. Used materials and drugs, 
are also introduced briefly.   
In the experimental part, methods for material characterization were differential 
scanning calorimetry, thermogravimetric analysis, capillary viscometric analysis, size-
exclusion chromatography and microcomputed tomography. Main interest was in drug 
release part, which was monitored using UV/VIS-spectrophotometer. Also initial drug 
contents were measured. 
Theory and real drug release behavior from biodegradable polymers are very com-
plex due to changes in material caused by constant changes in material. Aim was to rec-
ognize factors that affect the drug release profile and kinetics, and can be used to tailor 
properties of potential drug delivery devices.  
In the literature, there are some drug release studies related to similar polymers that 
are used here. However, these are mostly dealing micro- or nanoparticles where the 
PEG block is much smaller than what we have used in this work. These studies are also 
for shorter time periods. No publications of similar porous materials were found. Addi-
tionally, CO2 processing is relatively novel technique to prepare drug delivery devices.   
 3 3  
2 CONTROLLED DRUG RELEASE FROM BIO-
DEGRADABLE POLYMERS 
2.1 Principles of controlled drug release 
Controlled drug delivery means that active agent is combined with system which releas-
es drug in a controlled way (Saltzman 2001; Bader & Putnam 2014). These are called as 
drug delivery devices (DDDs). DDDs are implanted to a specific site where implant 
releases active agent over extended period of time. Local drug concentration is kept at 
desired level while unwanted side effects are minimized. (Bader & Putnam 2014). 
Conventionally drug is taken in oral doses. One dose is effective only short period 
of time. (Jones 2004)  Figure 1 presents how drug concentration varies between doses. 
Dotted line presents pulsatile dosage and solid line controlled release dosage. Plasma 
concentration should be kept inside the therapeutic window. It means that concentration 
is kept between maximum safe concentration and minimum effective concentration. 
(Bader & Putnam 2014) Orally taken drugs have many issues like poor patient compli-
ance. (Jones 2004) 
 
Figure 1. Schematic presentation of typical drug concentration as function of time. 
(Jones 2004) 
 
Different kinds of non-degradable drug delivery systems have been available for a while 
now. There is strong motivation to develop biodegradable DDDs. Conventional meth-
ods (for example oral pills) in drug delivery have different kinds of issues like unwanted 
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side effects and possible toxicity of drug. Newer methods can possibly solve many of 
them. Safety and efficacy of drugs can be improved and proteins and other difficult 
drugs need something else than conventional methods to be delivered for example. 
(Langer 1990) Biodegradable DDDs do not need removal surgery like non-degradable 
ones which is a great advantage. (Bader & Putnam 2014) Disadvantages of biodegrada-
ble DDDs are that these may be very complex and costs of development can be expen-
sive. (Kleiner et al. 2014) 
 
 
Figure 2. Schematic presentation of matrix device. Modified from (Bader & Putnam 
2014). 
 
There are several different kinds of drug delivery devices but in this work focus is in 
biodegradable matrix devices (Figure 2). Matrix device means that drug is homoge-
nously dispersed in a polymeric material. (Jones 2004) 
2.2 Drug release mechanisms from biodegradable poly-
mers 
2.2.1 Diffusion 
Diffusion can be described as random movement of substances (drug) from high con-
centration region to low concentration region (Jones 2004). There are several different 
factors that have an effect on diffusion. Physical properties have important role 
(Willerth & Sakiyama-Elbert 2007). Kinetics of release can be determined by concen-
tration gradient, diffusivity of substance inside polymer matrix and mean diffusion dis-
tance. (Szentivanyi et al. 2011) Fick’s First Law can be used to model simple one direc-
tion diffusion flux, J (mass flow/area):  
 
𝐽 = −𝐷
𝜕𝑐
𝜕𝑥
;               (1) 
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where D is the diffusion coefﬁcient, c solute concentration and x distance. (Siegel & 
Rathbone 2012) It is used when diffusion is expected to be steady state (Lao et al. 
2011).  
 
 
Figure 3. Typical release profile based on diffusion. (Szentivanyi et al. 2011) 
 
Figure 3 presents typical diffusion based drug release profile. In diffusion based devic-
es, the rate of drug release decreases with time because distance of diffusion increases 
(Siegel & Rathbone 2012). 
2.2.2 Bioerosion 
When release is controlled by erosion, diffusion of substance is negligible inside a pol-
ymer. Drug is released by degradation and erosion of matrix. (Szentivanyi et al. 2011) 
Polymer erosion is defined as decrease in mass and degradation as decrease in molecu-
lar weight (Bader & Putnam 2014; Szentivanyi et al. 2011; Lao et al. 2011). The rate of 
degradation is dependent on the availability of water molecules and how sensitive the 
chemical bonds of the polymer backbone (Szentivanyi et al. 2011). Material can be bulk 
or surface degradable. Difference between these two is illustrated in Figure 4. 
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Figure 4. Schematic presentation of bulk and surface eroding implants. (Bader & 
Putnam 2014) 
 
If polymer degradation is faster than water diffusion into polymer, polymer is surface 
erodible and vice versa because degradation is dependent on presence of water mole-
cules. (Bader & Putnam 2014). With surface erodible materials, the drug release often 
correlates well with mass loss of polymer. These are usually hydrophobic polymers. 
(Ratner et al. 2013) Polymer hydrophobicity/hydrophilicity has an important role on 
how polymer degrades (Szentivanyi et al. 2011; Bader & Putnam 2014). With surface 
eroding polymers, near zero order release is possible to achieve (Siegel & Rathbone 
2012). 
With bulk erodible polymers, diffusion of drug has important role (Ratner et al. 
2013). In Figure 5 different stages of drug release from erodible polymer are presented. 
For bulk eroding polymers typically burst effect is observed (Rich et al. 2002). This is 
because first the drug releases from surface and from pores near the surface (a in Fig-
ure). Usually, the aim is to finish the drug release before degradation starts (Rich et al. 
2002). Next stage is latent stage (b). Some degradation is seen, but some of the drug is 
trapped. Finally (c) rest of drug is released rapidly because of autocatalytic degradation. 
Polymers that degrades by bulk should not be used with drugs that have narrow thera-
peutic window (Siegel & Rathbone 2012). However, usually both, surface and bulk ero-
sion occurs at same time with polymers. 
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Figure 5. Schematic presentation of different stages of bulk eroding and drug releasing 
polymer. (Siegel & Rathbone 2012)  
 
There are three different ways for bioerosion. First group is water solubilized polymers 
that have been insolubilized. Solubility of the drug has to be taken into account because 
the drug is in aqueous environment. Well soluble drugs are released rapidly. Second 
group is water insoluble polymers that are solubilized by hydrolysis, ionization or pro-
tonation of a pendant group. Finally, the third group is hydrophobic polymers that are 
converted into water-soluble molecules by backbone cleavage. (Heller 1979) 
 
2.2.3 Chemical bond 
Drug can be covalently or non-covalently bonded to a polymer (Willerth & Sakiyama-
Elbert 2007). This allows protein and growth factor delivery in a way that active agent 
will not lose its activity (Pasut & Veronese 2007). However in design it has to be taken 
into account that drug will not lose its biological activity because of chemical reactions. 
(Willerth & Sakiyama-Elbert 2007). Usually drug is activated biologically when bond 
between drug and polymer is cleaved because of hydrolysis (Baker 1987). Hydrolysis is 
rate limiting factor in chemically releasing materials. (Baker 1987) Figure 6  illustrates 
different types of approaches to synthesize chemically controlled drug delivery device.  
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Figure 6. Different approaches to synthesize chemically bonded drug-polymer system. 
A is active agent, M is polymer and X is labile group. Modified from (Baker 1987) 
 
These can be classified into different groups: Drug (Type I) has already reactive group 
that is bonded to polymer backbone. If it does not contain reactive group, drug molecule 
can be manipulated to be reactive like in type II. Drug can be converted into derivative 
that can be polymerized (Type III) or vary rare situation (Type IV) where drug can be 
directly converted into polymer. (Baker 1987)  
2.3 Release kinetics 
In reality, erosion and diffusion occur at the same time which makes predicting of re-
lease kinetics difficult (Lee et al. 2003). There are numerous factors that have an effect 
on the process. For polymer degradation and drug release, at least crystallinity of poly-
mer, drug molecular size and solubility and morphology are factors that affect to these 
processes. (Lee et al. 2003) Crystallinity makes the material more close packaged which 
leads to decrease of diffusion. Thus, crystallinity is an important factor in drug release. 
Polymer backbone composition has an important role in controlling the rate of erosion. 
(Bader & Putnam 2014) 
Degradation of material is quite difficult to predict due to the physical changes in 
material during degradation. Even though degradation process is complex, release kinet-
ics of drugs can be similar with non-degradable ones. (Saltzman 2001) Also diffusivity 
of degrading material changes as function of time (Bader & Putnam 2014). Figure 7 
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presents how it affects the release profile. Black line presents degradable implant and 
gray line nondegradable implant.  
 
Figure 7 Difference between release profile of degradable and non-degradable bulk 
polymers. (Bader & Putnam 2014) 
 
Figure 8 presents typical release profiles based on diffusion, diffusion and bulk erosion 
and surface erosion.  
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Figure 8. Schematic presentation of different release profiles in different kinds of re-
lease mechanics.(Szentivanyi et al. 2011) 
 
Chemical properties of the polymer and the drug have great effect on the release. Drug 
distribution, molecular weight of polymer and polymer blending are also factors worth 
of mention. (Freiberg & Zhu 2004) Drug can be dispersed or dissolved in the polymer 
(Saltzman 2001). Usually release of hydrophobic drugs from hydrophobic material is 
very slow (Zilberman et al. 2010) and on the contrary well watersoluble drugs may re-
lease very rapidly as mentioned before. Lipophilic drugs often get trapped in the hydro-
phobic polymer resulting very slow release (Tamboli et al. 2013). Burst effect can be 
possibly reduced by forcing drug to dissolve/disperse better into polymer matrix by us-
ing surfactants or cosolvents. Also drug loading amount and porosity of material are 
important factors for burst effect. These are studies where has observed to have relation 
between these factors and burst effect. (Rothstein & Little 2011) 
Sample size and shape have an effect on the degradation rate (Yoon et al. 2003). 
When implants have defined geometry, it is possible to predict and simulate release 
(Bader & Putnam 2014). There are numerous different models available in literature. 
Probably the most known and successful model for matrix release system is Higuchi 
model. It is also based on Fick’s first law (Lao et al. 2011). However, it is for systems 
that do not go through erosion. Erosion causes changes in matrix by increasing permea-
bility of drug. (Heller 1979) 
With polyesters, it is known that the acidic degradation products catalyze the degra-
dation process (Szentivanyi et al. 2011). Size and shape of matrix has effect how sensi-
tive material is to catalysis (Lao et al. 2011). Figure 9 presents process of acid and alka-
line based hydrolysis. Carboxylic acid and alcohol are formed in the process.  
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Figure 9. Hydrolysis of ester in an acidic and alkaline environment (Bader & Putnam 
2014). 
 
When hydrolysis is acid catalyzed, the reaction has two stages. Free hydrogen associates 
with carbonyl while water acts as nucleophile. Tetrahedral intermediate is formed which 
makes alcohol to leave easily. In alkaline catalyzed environment, free hydroxyl anions 
acts as nucleophile. Again this nucleophile causes formation of tetrahedral intermediate 
which leading to alcohol elimination. Reaction goes on until polymer has degraded 
completely. (Bader & Putnam 2014) 
2.4 Degradation and drug release of porous materials 
It is known that porosity of material affects the degradation of material. However effect 
of pore size to degradation process is not well known yet. There are somewhat conflict-
ing results available. (Odelius et al. 2011) 
Degradation can occur faster with nonporous specimens because the products of 
degradation have easier path to the surrounding solution (Odelius et al. 2011). Especial-
ly, with polyesters’ acidic degradation products tend to cause an auto catalytic effect 
when acidic degradation products are trapped inside polymer matrix (Dash & 
Konkimalla 2012). Odelius et al. (2011) studied degradation of solid and porous 
PDLLA (L/D 96/4) films. Solid films and large pore sized samples degraded fastest. It 
was suggested that autocatalytic effect took place. Degradation products are thought to 
get trapped inside material. Smaller pore size samples degraded slower than the other 
samples. (Odelius et al. 2011) 
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Lu et al. (2000) studied degradation behavior of porous (70-90 -wt%) PLLA foams. 
Again, autocatalytic effect was thought to take place in in vitro degradation test series. 
They concluded that increase in pore wall thickness caused weight average molecular 
weight to decrease significantly due to autocatalysis. Degradation products can be 
trapped inside polymer matrix. (Lu et al. 2000) 
Pore structure also has an effect on the drug release kinetics (Siegel & Rathbone 
2012). Velasco et al. (2010) studied degradation of polymer and release of ibuprofen 
from porous Poly(methyl methacrylate)-Poly(lactide) blends processed using supercriti-
cal CO2. They concluded that swelling and degradation behavior were dependent on 
porosity and PLA content of samples. Release was faster from samples with higher 
swelling and degradation.  
Whang et al. (2000) studied protein release from highly porous PLGA scaffolds 
prepared using emulsion freeze-drying technique, having general porosity approximate-
ly 90%. Protein was added 0.1 mg/ml or 0.2 mg/ml in emulsion, and poresize was var-
ied between 7-70µm. It was concluded that smaller pore sized samples showed slower 
release rate than bigger pore sized samples having same amount of drug.  
Yoon et al. (2003) studied dexamethasone release from porous PLGA scaffolds. Re-
lease rate was dependent on the initial drug content. No burst effect was seen at begin-
ning of test series and release was controlled over 30 days. Released drug was able to 
suppress proliferation of lymphocytes and smooth muscle cells in in vitro.  
Martin et al. (2001) used porous polymer foams made of PLGA and PEG. Polymer 
were conjuncted with different molecules to differentiate bone marrow stromal cells 
into cartilaginous of bone-like tissues.     
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3 MATERIALS IN CONTROLLED DRUG RE-
LEASE 
3.1 Synthetic biodegradable polymers in drug delivery 
3.1.1 Polylactide 
Polylactide is an aliphatic polyester having repeating unit of lactic acid. Aliphatic poly-
esters are most studied polymers in therapeutic field (Kleiner et al. 2014; Bastioli 2005). 
There are two isomers that can be used. These are named as L- and D-lactic acid (Jones 
2004). These are presented in Figure 10. 
 
Figure 10. Isomers of lactic acid. (Auras et al. 2010) 
 
PLA is polymerized using ring opening polymerization of lactide, a dimer of lactid acid 
(Bastioli 2005). Structure of poly(lactide) is presented in Figure 11.  
 
Figure 11. Structure of Poly(lactide). (Jones 2004) 
Poly-L-lactide (PLLA) is a semi-crystalline polymer with melting temperature (Tm) of 
175-180 °C and glass transition (Tg) of 60 °C. It is brittle by nature and decomposes 
around 185 °C. L-lactic acid is usually copolymerized with D-lactic acid or other hy-
droxyacids to obtain better processing characteristics and lower Tg. (Bastioli 2005) Deg-
radation takes about 18-24 months (Saltzman 2001). On the contrary to PLLA, poly-
D,L-lactide (PDLLA) is amorphous and degrades in weeks (Bramfeldt et al. 2007). 
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Paakinaho et al (2009) studied in vitro degradation of PDLLA (96/4) with different mo-
lecular weights. It was concluded that rheological parameters affected also to degrada-
tion of material.  
PLA degrades into lactic acid by hydrolysis of ester bonds. Degradation products 
are removed from body by normal metabolic ways. (Lu et al. 2000) PLA hydrolysis can 
be autocatalyzed by acidic degradation products (Bastioli 2005). In drug delivery it is 
known to be less permeable than PCL  (Pitt et al. 1979). 
3.1.2 Poly(ε-caprolactone) 
Poly(ε-caprolactone)  (PCL) is a linear thermoplastic biodegradable polyester (CRC 
n.d.). It is semi-crystalline and has relatively polar ester group and five non-polar meth-
ylene groups (Wei et al. 2009; Tamboli et al. 2013). Structure of PCL is presented in 
Figure 12. It has low Tg around -60 C (Bastioli 2005; Bramfeldt et al. 2007) and Tm 
around 59-64 C (Saltzman 2001). PCL is more flexible and more hydrophobic than 
PLA. (Bastioli 2005) It is known from very good biocompability (Dash & Konkimalla 
2012) and from good permeation to drugs (Bramfeldt et al. 2007). Its hydrophobic na-
ture makes encapsulation efficiency of lipophilic drugs good (Tamboli et al. 2013). It 
also has excellent miscibility with many polymers (Hiljanen-Vainio et al. 1996). 
 
 
Figure 12. Structure of PCL. (Jones 2004) 
 
PCL is synthetized by ring opening polymerization of ε -caprolactone  (Wei et al. 2009). 
Degradation takes approximately 30 months depending on conditions of environment 
(Saltzman 2001). Degradation starts from amorphous regions and it is autocalatyzed by 
carbonyl end group that fragments from matrix. Water permeability into material is rate 
limiting factor in degradation process. It takes from 4 to 6 months for start of mass loss. 
(Dash & Konkimalla 2012) It degrades slower than PLA, which makes it suitable for 
longterm applications (Saltzman 2001). However, copolymerization leads often to faster 
degradation (Saltzman 2001). Physical, chemical and mechanical properties can be tai-
lored by copolymerizing or blending with other polymers. Copolymerization is often 
done with other hydrophilic monomers. (Dash & Konkimalla 2012) 
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3.1.3 Poly(ethylene glycol) 
Poly(ethylene glycol)  (PEG) is also known as poly(ethylene oxide) (PEO). Structure of 
PEG is presented in Figure 13. It is synthetized from ethylene oxide by ring opening 
(Pfister & Morbidelli 2014).  
 
 
Figure 13. Structure of poly ethylene glycol. (Jones 2004) 
It is hydrophilic polymer having high solubility in water but also in various organic sol-
vents (Saltzman 2001; Pfister & Morbidelli 2014; Bramfeldt et al. 2007). Water mole-
cules bind to PEG structure (Pfister & Morbidelli 2014). PEG has excellent biocompati-
bility. It does not go through hydrolysis but incorporation into copolymer backbone has 
shown to have role in degradation process. Incorporation of PEG into polymer back-
bone has shown to have increasing effect on degradation. It makes material more hy-
drophilic and water uptake higher. (Bramfeldt et al. 2007) 
PEG gives opportunity for many different kinds of drug release systems. There are 
numerous studies of different protein delivery systems (Veronese & Pasut 2005) In gen-
eral, it increases the solubility of drugs (Zhang & Zhuo 2005) Hydroxyl groups of PEG 
allow copolymerization with lactides, glycolides and caprolactone for example (Li et al. 
1998). 
Excretion from body can be an issue. Normally, it is excreted in urine or feces but 
high molecular weight PEG may accumulate to liver, which may lead to macromolecu-
lar syndrome. (Veronese & Pasut 2005) However molecular weight below 20 000g/mol 
filtrates though kidneys. (Li et al. 1998) 
 
3.1.4 Poly(L-lactide-co-caprolactone) 
Structure of Poly(L-lactide-co-caprolactone), P(LA-co-CL) is presented in Figure 14.  
 
Figure 14. Structure of P(LA-co-CL). (Saltzman 2001) 
 
 Ahola et al. (2013) Studied hydrolytic degradation of Poly(L-lactide-co-caprolactone) 
with the comonomer ratio of 70/30 with different β-TCP contents (0-50%). TCP did not 
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have effect on the degradation of the matrix. Composites absorbed water more than 
plain polymer. For all samples, the mass loss was very small during the first ten weeks. 
Water absorption of plain polymer increased rapidly after 20 week time point. Tgs of 
samples decreased until 12th week timepoint was reached. It was same time point when 
molecular weights started to decrease rapidly. Melting temperatures increased from 2nd 
week time point to 16
th
 week time point from 111-113°C to 116-120°C. After 16
th
 week 
melting points decreased constantly. (Ahola et al. 2013) 
Ahola et al. (2012) Studied hydrolytic degradation and in vitro rifampicin release 
from composites of Poly(L-lactide-co-caprolactone) 70/30 and β-TCP. Degradation of 
materials obeyed first order kinetics. Decrease of molecular weight was relatively rapid. 
Composites including rifampicin degraded more rapidly at beginning of test series than 
samples without TCP. Mass loss and water absorption started earlier than in study of 
ciprofloxacin release (Ahola et al. 2013). It was suggested that Rifampicin’s more hy-
drophilic nature caused this kind of behavior. Four different phases were found during 
release. Samples without ceramic fillers had quite long lag phase at start. (Ahola et al. 
2012) 
In drug release applications P(DLLA-CL) with block structure is known from burst 
effect and poor water absorption after amorphous lactide units has degraded rapidly. It 
is not kind of behavior that is needed in drug release applications. However, more ran-
domized structure may degrade in more stable way and show more controlled drug re-
lease behavior. Additionally, by varying ratio of LA/CL unit, it is possible to control the 
degradation of polymer. (Bramfeldt et al. 2007) 
Pitt et al. (1979) studied steroid release from P(DLLA-CL) with five different drugs 
and varying LA/CL ratio. PDLLA were 1000 times less permeable than PCL. Since 
PDLLA is totally amorphous the poor permeability was thought to be cause from de-
crease of free volume. However it was significantly increased by using additives. Co-
polymers of D,L-lactide and caprolactone had good permeabilities. (Pitt et al. 1979)   
in at study of Hiljanen-Vainio et al. (1996) degradation of copolymers of caprolac-
tone and lactide were studied. Ratio of LA/CL and type of lactide varied. Properties of 
polymers varied from very elastic materials to tough material. Mechanical values such 
as tensile modulus and tensile stress were higher with every homopolymer compared to 
copolymers but maximum strains were relatively low. Malin et al (1996) continued deg-
radation study of copolymers of caprolactone and lactide. Also pure PLLA, PDLLA and 
PCL were studied as comparison. Molecular weights of copolymers decreased rapidly at 
beginning of hydrolysis. However, any significant mass loss was not seen. (Malin et al. 
1996)  
Water absorptions were for PLLA, PDLLA and PCL after 1 week 4.7, 20.4 and 0.5-
wt% respectively. After two week timepoint, PDLLA absorbed 38.6-wt% water and was 
not measurable after that. During 7 week hydrolysis crystalline PLLA absorbed 18.3-
wt% of water while PCL did only 0.1-wt%.  (Malin et al. 1996) Karjalainen et al. (1996) 
continued research by studying changes in mechanical properties after in vitro of same 
materials that was used Malin et al (1996) in their study. Copolymers kept their me-
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chanical properties like tensile modulus better than homopolymers of lactide. Homopol-
ymer of caprolactone kept its properties almost at same during 70 days of hydrolysis at 
23 °C. (Karjalainen et al. 1996) 
Copolymers of ɛ-CL and D,L-LA were also studied by Hiljanen-Vainio et al. 
(1997). Content of ɛ-CL was varied between 5 to 30-wt%. Again, dramatic weight loss 
was seen by following mass loss weeks later. Tensile tests were performed to materials. 
Mechanical properties varied from hard and brittle to rubbery like material. ɛ-CL brings 
elasticity to material.    
Monomer content has very important role for properties of material. Having 85-wt% 
of DL-lactide and 15-wt% ɛ-CL makes material rubberylike, but increasing DL-LA con-
tent to 90-wt% changes properties to rigid.  (Hiljanen-Vainio et al. 1997) 
 
3.1.5 Poly(lactide-co-caprolactone)-poly(ethylene glycol) 
Lactides, glycolides and caprolactone give numerous opportunities to create interest-
ing materials. Properties can be tailored with varying different factors like for example 
lactide/caprocatone ratio and type of lactide monomer. It is not surprise that there are 
also studies related to different combinations available. 
For example Bramfelt et al. studied P(CL-co-DLLA)-PEG-P(CL-co-DLLA) copol-
ymers and effect of CL/DLLA ratio to degradation and material properties. They no-
ticed that PEG was able to crystallize in this kind of material. Additionally, it was no-
ticed that presence of D,L-LA had reducing effect to PCL crystallinity. It was clear that 
higher LA-content was consistent with higher water absorption and increasing mass 
loss. PEG had role of increasing hydrophilicity. (Bramfeldt et al. 2007) 
Cho et al. studied effect of PCL/PDLLA unit composition to degradation of P(D,L-
LA-ran-CL)-b-PEG-b-P(D,L-LA-ran-CL) films, where lactide and caprolactone have 
random structure with PEG block in the middle of polymer chain. Mw of PEG was 200 
g/mol while D,L-LA/CL ratio varied. Water absorption and mass loss were greater 
when D,L-LA/CL ratio was increased. It was explained by reduced crystallinity. (Cho & 
An 2006) Water absorption rates were less in this study than in Bramfeldt’s study. It 
was suggested that that was due to smaller PEG segments (Bramfeldt et al. 2007).   
Li et al studied degradation of PLLA-PEG-PLLA block copolymers. Mw of used 
PEG was 1800g/mol. Ratio of LLA/EG was varied and it was noticed that PEG chain 
length had significant effect to water absorption and mass loss. Polymers were prepared 
using CaH2 or Zn as coinitiator in synthetization. Used coinitiator had effect to these 
properties. It was suggested that CaH2 prepared polymers were more random than Zn 
which leads to more amorphous samples. (Li et al. 1998) 
Tamboli et al. (2013) prepared (PLA-PCL-PEG-PCL-PLA) pentablock nano-
copolymers to study release of hydrophobic molecules. Different ratios of 
PEG/PCL/PLA were studied. Also the effect of L- and D-forms of lactide was studied. 
Degradation was faster compared to pure PLA and PCL. Slow release of triamcinolone 
acetonide, a corticosteroid, was observed from polymers PLLA-PCL-PEG-PCL-PLLA 
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(1/2,5/2,5 ratio) and PDLLA-PCL-PEG-PCL-PDLLA (1/2,5/2,5 ratio) which crystallini-
ty and hydrophobicity were low compared to other studied polymers. Release was con-
tinuous for 35 days and burst effect was also relatively small. It was suggested that in-
corporation of lactic acid into copolymer reduced burst. (Tamboli et al. 2013) 
Karjalainen et al. (2000) studied drug release of theophylline and propranolol (in-
cluding 2-30-wt%) from P(CL-DLLA) copolymers prepared using glycerol, PEG 1000 
or PEG 4000 as initiators. Increase of hydrophilicity resulted in higher release rates with 
both model drugs. PEG incorporation into backbone increased water uptake and rate of 
degradation.  
3.2 Model drugs in release study  
3.2.1 Dexamethasone 
Dexamethasone ((11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-
3,20-dione) has a molecular formula of C22H29FO5 and molecular weight of 392,46 
g/mol. It has a melting point of 262 °C and solubility in water is only 0,09
 
g/1000g at 25 
°C (Heynes 2014). Dexamethasone has hydrophobic nature (Yoon et al. 2003). Struc-
ture of dexamethasone is presented in Figure 15. 
 
Figure 15. Structure of dexamethasone. (ChemSpinder n.d.) 
 
Dexamethasone is a glucocorticoid, synthetic steroid having anti-inflammatory effects 
(Willerth & Sakiyama-Elbert 2007; Yoon et al. 2003). It is commonly used to treat ar-
thritis and sclerosis (Willerth & Sakiyama-Elbert 2007) 
Dexamethasone inhibits smooth muscle cell proliferation and has an important role 
in regulation of cellular growth and division. It has been used to inhibit abnormal migra-
tion and proliferation of smooth muscle cells after restenosis. (Yoon et al. 2003) 
Dexamethasone is traditionally used in osteoblast cell culturing (Wu et al. 2011). 
Martin et al. (2001) used dexamethasone with growth factor to guide bone marrow stem 
cells into osteoblast stem cells. 
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3.2.2 Vitamin C and its derivatives 
Ascorbic acid or commonly vitamin C has molecular weight of 176,126 g/mol and sol-
ubility in water 246
  
g/1000g at 25 °C. (Yaws 2012) 
Ascorbic acid is simple vitamin and was the first one to be isolated and purified. 
(Davies et al. 1991) Structure of ascorbic acid is presented in Figure 16 and one of its 
salt derivatives, 2-Phospho-L-ascorbic acid trisodium salt, in Figure 17. 
  
Figure 16. Structure of vitamin C. (ChemSpinder n.d.) 
 
 
 
Figure 17. Structure of 2-Phospho-L-ascorbic acid trisodium salt. (ChemSpinder n.d.) 
 
It is the most industrially produced vitamin but also naturally found throughout in plant 
and animal kingdom. Its role is not very well understood in many of the processes it is 
involved. (Davies et al. 1991) It is commonly used in cosmetics and dermatological 
products. (Špiclin et al. 2003; Huang et al. 2013) It is an antioxidant and destroys oxi-
dizing agents and free radicals that are involved in skin aging process but it is known to 
simulate collagen synthesis too (Špiclin et al. 2003). 
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However, it is very unstable so usually more stable derivatives are used (Špiclin et al. 
2003)  
It is known to easily oxidized by dioxygen (O2). It is also commonly used in food 
industry. It can be used as an additive like for example improve taste and nutritional 
value, act as stabilizer or prevent oxidation in food (Davies et al. 1991) 
In medical field, it has had many uses too. It is often used with other drugs. It has 
been used in osteogenic cell differientiation with dexamethasone and beta-
glyserophosphate. (Wang et al. 2010) 
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4 MATERIALS AND METHODS 
4.1 Materials 
Medical grade Poly(L-lactide-co-ε-caprolactone)  70/30 was purchased from Corbion, 
Gorinchem Netherlands (code PLC 7015) to be used as comparable to experimental 
polymers. For polymerization of experimental polymers, ɛ-caprolactone (Fluka, Buchs, 
Switzerland) was used as distilled and D, L- lactide (Corbion, Gorinchem, Netherlands) 
was dried in vacuum and used as received. 0.05mol-% Sn(II)octoate (stannous 2-
ethylhexanoate) (Sigma-Aldrich, Steinheim, Germany) was used as catalyzer and used 
as received. 0.035% co-initiator polyethylene glycol, dried in vacuum, was used as re-
ceived.  
Used drugs were 2-phospho-L-ascorbic acid trisodium salt having purity of 95% 
(C6H6Na3O9P*xH2O, Lot: # BCBM4646V, Sigma, Germany) and Dexamethasone 
(C22H29FO5, Lot # BCBK5387V, Sigma ) having purity of 98%. Drugs were used as 
received. 
For Sörensen buffer solution, prepared using standard of ISO 15814 (Implants for 
surgery - copolymers and blends based in polylactide – in vitro degradation testing), 
potassium dihydrogen phosphate (KH2PO4) (J.T. Baker, Netherlands) and sodium phos-
phate dibasic anhydrous (Na2HPO4) (J.T. Baker, Netherlands) were used.  
 
Table 1. Polymers used in in vitro drug release study. 
Copolymer CL-content 
(mol fracti-
on) 
LA-content 
(mol fracti-
on) 
Type of 
lactide 
PEG in 
backbone 
P(CL30/LLA70) (Corbion, 
Netherlands) 
30 70 L - 
PEG-P(CL30-LLA70) 30 70 L yes 
PEG-P(CL30-DLLA70) 30 70 DL yes 
PEG-P(CL15-DLLA85) 15 85 DL yes 
 
Materials used for the in vitro drug release test series are listed in Table 1. First material 
is fully commercial and last tree was polymerized in Aalto university (Espoo, Finland) 
by Sanja Asikainen. Size of PEG block was 20 000 g/mol. Numbers following mono-
mer abbreviations are mol fractions in feed. Structures of used copolymers are presented 
in Figure 18.  
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Figure 18. Chemical structures of used copolymers. 
A structures of used drugs were presented already in chapter 3.2. Dexamethasone 
(DEX) is in Figure 15 and a derivative of ascorbic acid salt (AAs), 2-phospho-L-
ascorbic acid trisodium salt, in Figure 17. 
4.2 Methods 
4.2.1 Polymerization and preparation of samples  
Reactor was flushed with nitrogen for 15 minutes and 10 minutes when all reagents 
were inside. Reactor was closed and heated up to 160 °C. Polymerization times were 
3hours 15minutes for PEG-P(CL30-LLA70), 4hours 30 minutes PEG-P(CL30-
DLLA70) and 4hours 20 minutes for PEG-P(CL15-DLLA85).  
Polymers were dissolved into dichloromethane and precipitated from ethanol and 
removed from liquid using tweezers. Polymers were left in fume chamber to dry over 
night and later in desiccator.  
Before blending drugs with polymer, materials were dried in vacuum at least 24 
hours. Polymer and drug was fed in turn into twin screw midi-extruder (DSM, capacity 
of 16 cm3 with screw length 150 mm) under nitrogen atmosphere. Blend was taken out 
once and feeded in again. After everything was inside, blend was used as a batch mixer 
for 2 minutes. Speed of the screw was 65 rpm. Temperatures for P(CL30/LLA70), PEG-
P(CL30-LLA70), PEG-P(CL30-DLLA70) and PEG-P(CL15-DLLA85) during extru-
sion were 145 °C, 135-140 °C, 125°C and 95-100°C respectively.  
After extrusion, materials were compression molded (Fortune TB 400, Holland). 
Maximum weight of 5 grams of sample material were weighted for the mold. Preheating 
was 5 minutes long and so was the actual compression. 150 kN pressure were used. Pa-
rameters during extrusion and compression molding are found in Table 2.  
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Table 2. Processing and compression molding temperatures of polymers. 
Material Temperature 
during extrusion 
(°C) 
Compression 
molding tempera-
ture (°C) 
Cooling time (s) 
P(CL30/LLA70) 135-140 145 30 
PEG-P(CL30-LLA70) 145 155 45 
PEG-P(CL30-DLLA70) 125 125 10 
PEG-P(CL15-DLLA85) 95-100 100 10 
 
Maximum number of samples that were possible to make at once were 100. Shape of 
the samples were cylinders with 5 mm diameter and height approximately 2 mm. Com-
pression molding was done in Aalto university (Espoo, Finland) by Sanja Asikainen. 
For porous samples, supercritical carbondioxide (sCO2) was used to achieve porous 
structure. Processing was done using high pressure and temperature in presence of CO2.  
Processing method does not contain any toxic solvents which makes it tissue friendly 
(Davies et al. 2008). sCO2 processing was done in Tampere University of technology 
(Tampere, Finland) by Kaarlo Paakinaho. 
4.2.2 Inherent viscosity 
Capillary viscosimetry was used for analyzing inherent viscosities. Measurements were 
done using Lauda capillary viscometer (Lauda-Königshofen, Germany) with Ubbelohde 
capillars (Schott-Instrument, Mainz, Germany) with chloroform as solvent at 25 °C. 
Results were used to predict processing parameters when samples were CO2-processed. 
Additionally, results were used to compare drug release and how viscosity affects to 
that, even though viscosity is not proper parameter because polymer matrix does not 
flow like liquid (Siegel & Rathbone 2012). Two parallel samples were used for the 
samples without any drug. Sample sizes were around 20mg.   
4.2.3 Size-exclusion cromatography 
Size-exclusion chromatography (Water Associates system equipped with a Waters 
717plus autosampler with waters 510 HPLS solvent pump and four linear gel columns 
(10
4
, 10
5
, 10
3
 and 100 Å) connected to series and Waters 2412 differential refractome-
ter) were used to measure molecular weights.  
Number of parallel of samples was 2, except for samples containing drug it was 1. 
Polystyrene standards were used for calibration. SEC was used to measure Number av-
erage (Mn) and weight average (Mw) molecular weights and polydispersities (PD) of the 
samples after compression molding. Also samples processed with supercritical CO2 
without drugs were analyzed. Chloroform was used as solvent and eluent. Measure-
ments were done in Aalto university (Espoo, Finland) by Sanja Asikainen. 
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4.2.4 Ultraviolet/visible-spectrophotometer 
In this work Unicam UV 500 was used (Thermo Spectronic, Cambridge, England) with 
1cm cuvette and Sörensen phosphate buffer solution or chloroform as solvent. Analysis 
was done to measure released drug from in vitro samples. Also initial drug contents 
were measured by dissolving samples in chloroform. For each different drug and sol-
vent, calibration curves were ran. Released drug were calculated using following equa-
tion: 
 
 𝑅𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑑𝑟𝑢𝑔 [
𝜇𝑔
𝑚𝑔⁄ ] =
𝑐𝑣
𝑚
            (2) 
 
where, c is measured concentration, v is volume of buffer solution and m is mass of 
measured sample. 
For measuring the initial content of drug, approximately 20 mg dexamethasone 
samples were dissolved in 50 ml of chloroform. Parallel of samples were 5. Standard 
lines were determined for both drugs in solvent. For ascorbic acid, standard line in water 
was y=0.0334x (R
2=0.999, λ=260nm, n=11) and for dexamethasone in chloroform 
y=0.0347x (R
2=0.9979, λ=246nm, n=9). 
Standard lines were done for both drugs in Sörensen phosphate buffer solution. For 
both drugs, plot remained linear up to 40 µg/mg concentration. In higher concentrations, 
the curve did not remain linear. Measured standard lines are found in Figure 19 for dex-
amethasone and Figure 20 for ascorbic acid salt. 
 
 
Figure 19. Standard line of dexamethasone in buffer solution (n=11). 
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Figure 20. Standard line for AAs in buffer solution (n=9). 
 
Measurements of different scans were done in range of 190-600 nm and values in the 
peaks of curves were used for standard lines. For dexamethasone measurements got 
highest values at 241nm and for AAs at 260nm.  
 
4.2.5 In vitro drug release test series 
Six parallel test series were started by weighting samples using analytical scale (Mettler 
Toledo, AG 245) after storing them in vacuum at least 3 days. 10 ml of Sörensen buffer 
(pH 7.4, prepared using ISO-15814 standard) was measured to each brown glass bottle 
with samples. These were kept in shaking incubator at 37 °C and 100 rpm. Measure-
ments of released drug was done using UV/VIS-spectrophotometry scanning samples in 
range of 190-450 nm, to make sure that there was no air bubbles to interfere measure-
ments. 
 
4.2.6 Microcomputed tomography 
Microcomputed tomography (µCT) was used for visual examination of porous samples. 
Also porosity, mean pore size and standard deviation and area of sample were analyzed. 
µCT imaging (Carl Zeiss X-ray Microscopy Inc., Pleasanton, CA, USA) was done using 
80 kV source voltage, 125 µA source current and 6.2µm voxel size. Reconstruction was 
done using Xradia’s XMReconstructor software. For manual image segmentation was 
used a Fiji, an opensource software. Analysis was done using same software with BoneJ 
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plugin. All imaging and image analysis was done in Tampere university of technology 
(Tampere, Finland) by Markus Hannula.  
 
4.2.7 Thermal analysis 
Thermal analysis was done using differential scanning calorimetry (DSC) and thermo-
gravimetric analysis (TGA). DSC was used to measure glass transition temperatures 
(Tg) and melting temperatures (Tm). Five parallel samples were used due to relatively 
high standard deviation of samples. DSC run was done using DSC Q1000 (TA Instru-
ments, Delaware, USA) under nitrogen. Two heating scans were made (20°C/min) from 
-20°C to 200°C with 1 minute stand at 200°C and cooling at rate of -50°C/min. Tgs were 
analyzed from second heating and Tms from the first. For the analysis of the results, TA 
Universal analysis software was used. 
Due to high melting point of both drugs and lower decomposion of polymers used, 
heat could not rise high enough to see if there is going to be a melting peak or not. It 
would tell whether the drug is dissolved or dispersed in polymer matrix. It was decided 
to run thermogravinometric analysis to get possibly some information of thermal behav-
ior near drug melting point. Analysis was done by heating at rate of 20°C/min up to 600 
°C under air atmosphere. TGA 500 (TA Instruments, Delaware, USA) were used for 
measuring and analysis were done using same software as were used in analyzing DSC 
samples. Only one sample was ran for each polymer-drug combination.  
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5 RESULTS AND DISCUSSION 
 
5.1 Molecular weight 
Weight average (Mw) and number average (Mn) molecular weights of porous and non-
porous samples without drug are listed with the measured polydispersities (PD) in Table 
3. It seems that processing samples with supercritical CO2 affects by reducing molecular 
weights slightly. However, GPC as an analysis method is not very accurate and differ-
ences of few thousand g/mol may not be significant. Samples were tested after pro-
cessing, before starting drug release test series.    
 
Table 3. Measured Mw and Mn for porous and nonporous polymer samples (n=2). 
 Solid samples Porous samples 
Polymers Mw Mn PD Mw Mn PD 
P(CL30-LLA70) 235000 142000 1.65 232000 140000 1.66 
PEG-P(CL30-LLA70) 78000 50000 1.56 65000 45000 1.44 
PEG-P(CL30-
DLLA70) 
152000 88000 1.73 138000 92000 1.50 
PEG-P(CL15-
DLLA85) 
220000 147000 1.50 157000 97000 1.62 
 
Molecular weights of solid samples with drugs are listed in Table 4.  
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Table 4. Measured Mw, Mn and PD values of used polymer-drug combinations (n=1) 
(A=ascorbic acid salt, D=dexamethasone and 4,8=weight contents of drugs). 
Material Mw Mn PD 
P(CL30-LLA70) 235000 142000 1.65 
A4 225000 142000 1.58 
A8 201000 128000 1.57 
D4 233000 139000 1.68 
D8 230000 136000 1.69 
PEG-P(CL30-LLA70) 78000 50000 1.56 
A4 67000 40000 1.68 
A8 53000 31000 1.71 
D4 84000 57000 1.47 
D8 82000 54000 1.52 
PEG-P(CL30-DLLA70) 152000 88000 1.73 
A4 130000 83000 1.57 
A8 122000 80000 1.53 
D4 145000 92000 1.58 
D8 149000 95000 1.57 
PEG-P(CL15-DLLA85) 220000 147000 1.50 
A4 206000 141000 1.46 
A8 177000 103000 1.72 
D4 210000 139000 1.51 
D8 227000 153000 1.48 
 
 
With dexamethasone samples, molecular weights remains almost at same level except 
there is small increase with PEG-P(CL30-LLA70). Decrease in molecular weights was 
observed for samples containing ascorbic acid salt derivative. PD values are in between 
1.46 and 1.73. Molecular weights were expected to have effect to degradation of materi-
als and release of drugs. 
5.2 Inherent viscosity 
Measured inherent viscosities are in Table 5. Measured molecular weighs are well in 
consistent with measured i.v results. 
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Table 5. i.v results of used polymers. (n=2) 
Material Viscosity (dl/g) 
P(CL30-LLA70) 0.99 
PEG-P(CL30-LLA70) 0.76 
PEG-P(CL30-DLLA70) 1.29 
PEG-P(CL15-DLLA85) 1.56 
 
PEG-P(CL30-LLA70) has the smallest measured i.v. value (0.76 dl/g) and molecular 
mass (Mw of 78 000g/mol) compared to other results. Also release rates were fastest for 
this material compared to corresponding combinations of other materials. Drug mole-
cules were released easily from this material. However, low viscosity and molecular 
mass was not probably only reason why drug release was fast and did not dominate re-
lease. Ethylene glycol incorporation into polymer backbone has made it more hydro-
philic than commercial P(CL30-LLA70). Especially AAs has easy escape from materi-
al. General porosity were smallest however. 
PEG-(CL15-DLLA85) has Mw of 220 000 g/mol and i.v. 1.56 g/mol but dexame-
thasone  release was faster than from PEG-(CL30-DLLA70) which did not have that 
high values (Mw of 152 000 g/mol and i.v. 1.29 g/mol). Inherent viscosity does not ex-
plain difference here. Reason could be better permeability caused by higher caprolac-
tone-content of copolymer PEG-(CL30-DLLA70). Release rate of AAs from PEG-
(CL15-DLLA85) was slightly higher than from PEG-(CL30-DLLA70).  
5.3 Stability of drugs 
Stability test was done to both of the drugs. Solution of drug and buffer solution 
(40μg/ml) was prepared and stored in a refrigerator (2 ˚C) and shaking incubator (37 ˚C, 
100 rpm). Dexamethasone containing samples were placed in test tubes and sealed with 
rubber corks. It was noticed that used corks did not manage to keep evaporated solution 
inside container. This was seen as increase in measured absorbance. Test tubes were 
decided change to brown 25ml bottles with screw caps which were used already in 
measuring AAs samples. For AAs, some changes in concentration were seen during one 
week test period. For cold stored samples, concentration decreased 0.8 % and for incu-
bator stored 4,8% from initial drug content of prepared solution. 
5.4 Initial drug content 
The solutions were measured using UV/VIS-spectrometer. Pipetting of chloroform was 
difficult due to low viscosity that makes it leaking out of pipette. Additionally, when 
initial drug contents were measured, lamps of UV/VIS-spectrometer started to lose their 
power. This could possibly have an effect to measurements. 
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There was not found any significant difference in dexamethasone contents between 
solid and porous samples. However all samples included less drug that theoretically 
there should have been. It is possible that some of the drug was left to feeder during 
blending but likely it is not the only reason why some are missing. Drug may have de-
stroyed in processing because of heat for example. With PEG-P(CL15-DLLA85) sam-
ples that should have contained 8-wt% dexamethasone, the standard deviations were 
relatively high. It was 3.93 for solid samples and 3.20 for porous samples. It is interest-
ing since dexamethasone blended well with used polymers. Possibly polymer may have 
become saturated from drug and the rest of the drug is in dispersed form. Measured ini-
tial contents of dexamethasone containing samples are found from Table 6. 
 
Table 6. Measured drug content of dexamethasone (n=5). 
Material Theoretical 
content (%) 
Average 
drug con-
tent (%) 
Standard de-
viation 
Average 
drug con-
tent in 
porous 
samples(%) 
Standard 
deviation of 
porous 
samples 
P(CL30-
LLA70) 
4 3.48 0.12 3.50 0.11 
 8 6.30 0.22 6.48 0.10 
PEG-P(CL30-
LLA70) 
4 3.66 0.26 3.45 0.25 
 8 6.53 0.10 6.61 0.11 
PEG-P(CL30-
DLLA70) 
4 3.30 0.49 3.38 0.66 
 8 7.07 0.04 7.48 0.18 
PEG-P(CL15-
DLLA85) 
4 3.71 0.09 4.06 0.13 
 8 7.25 3.93 9.57 3.20 
 
 
Because AAs is soluble only into water and some organic solvents, drug content was 
chosen to be measured by using extraction. Used solvents were chloroform and distilled 
water. Solubility of AAs into chloroform should be negligible. there is not much data 
available about solubility’s of ascorbic acid deviations, but ascorbic acid is insoluble in 
many organic solvents including chloroform (Anon 2012). Extraction was done by first 
dissolving samples (n=5) into 20 ml of chloroform. Then the solution was poured into a 
separating funnel. Measuring flask was rinsed with distilled water to get all drug to fun-
nel. Extraction was done tree times. Results of initial drug contents of ascorbic acid salt 
containing samples are found from Table 7. 
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Table 7. Measured drug content of AAs (n=5). 
Material Theoretical 
content (%) 
Average 
drug content 
(%) 
Standard 
deviation 
Average drug con-
tent in porous sam-
ples(%) 
Standard 
deviation 
of porous 
samples 
P(CL30-
LLA70) 
4.00 3.11 0.41 2.80 0.39 
 8.00 6.95 0.75 6.62 0.31 
PEG-
P(CL30-
LLA70) 
4.00 1.44 0.25 3.62 1.69 
 8.00 4.26 1.14 3.82 0.49 
PEG-
P(CL30-
DLLA70) 
4.00 2.11 0.41 2.31 0.32 
 8.00 5.46 0.56 5.52 1.27 
PEG-
P(CL15-
DLLA85) 
4.00 3.44 0.49 3.02 0.58 
 8.00 7.20 0.44 6.44 1.10 
 
 
Again with every polymer-drug combination, measured contents were less than theoret-
ical ones. Also drug contents did not change much during CO2-processing. There were 
some combinations where standard deviations were relatively high. Results of PEG-
P(CL30-LLA70) 4-wt% including ascorbic acid salt were interesting. For solid samples, 
measured drug content was 1.44-wt% and for porous it was 3.62. This was the same 
material which processing temperature was highest causing samples turning into yel-
lowish. It was thought that some kind of reaction may have happened. However, with 
these measured drug contents, the actual drug release profiles seems more reasonable 
than using theoretical contents. 
Measuring AAs content was a bit problematic since there was some white thick pre-
cipitation present at measurements. It appeared either on water or chloroform phase and 
no logic was found in the behavior. There were differences between parallel samples 
too. Use of higher solvent volume could have helped on this issue. However, the results 
seemed reasonable.   
5.5 Drug release of dexamethasone 
Drug concentration of the buffer solution was followed periodically, at least once a 
week. After measurement, the whole buffer solution was changed to fresh. From meas-
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ured absorbance and known mass of sample and volume of buffer, the released amount 
of drug was calculated by using Matlab software. Calculations were done using equa-
tion (2). Cumulative releases were calculated from sums of measured released drugs and 
percentage release by dividing former result by initial drug content. Cumulative drug 
release from materials of P(CL30-LLA70), PEG-P(CL30-LLA70), PEG-P(CL30-
DLLA70) and PEG-P(CL15-DLLA85) are presented in Figure 21, Figure 22, Figure 23 
and Figure 24 respectively. Release curves are presented with error bars that are equal 
to standard deviations. p before abbreviations means that samples were porous and 
numbers 4 and 8 denote weight per cents of drug in the samples.  
 
 
Figure 21. Cumulative dexamethasone release from P(CL30-LLA70) where p is used to 
mark porous samples, D means that sample includes dexamethasone, and number after 
D is theoretical drug content. 
 
Release of dexamethasone from solid P(CL30-LLA70) was very slow during 120 days 
in vitro test series (Figure 21). It looks like the degradation and erosion of matrix was 
controlling the release of dexamethasone. From porous samples the release kinetics was 
quite close to zero-order kinetics.  
Figure 22 presents release of dexamethasone from PEG-P(CL30-LLA70). Lot of 
similarities can be found compared to the commercial material. Here also, the drug is 
released quite steadily from solid samples. Slight difference in release profile is possible 
to see and rates are slightly higher.  
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Figure 22. Cumulative dexamethasone release from PEG-P(CL30-LLA70) where p is 
used to mark porous samples, D means that sample includes dexamethasone, and num-
ber after D is theoretical drug content. 
 
When type of lactide monomer was changed from D-lactide to DL-lactide, the release 
pattern became very different than it was with PEG-P(CL30-LLA70) compared to PEG-
P(CL30-DLLA70). Release profiles are presented in Figure 22 and Figure 23 respec-
tively. There is a relatively long lag period before release starts. It looks like the release 
occurs by erosion of the material. Solid samples degraded relatively fast because of au-
tocatalysis. Measurements were finished when samples were so degraded that meas-
urements would not be reliable anymore. Solution did not look homogenous anymore. It 
became blurry after breakdown of samples. Basically shells of polymers were left when 
measurements were finished, which supports the suggestion of autocatalysis.    
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Figure 23. Cumulative dexamethasone release from PEG-P(CL30-DLLA70) where p is 
used to mark porous samples, D means that sample includes dexamethasone, and num-
ber after D is theoretical drug content. 
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Figure 24. Cumulative dexamethasone release from PEG-P(CL15-DLLA85) where p is 
used to mark porous samples, D means that sample includes dexamethasone, and num-
ber after D is theoretical drug content. 
 
Last polymeric material was PEG-P(CL15-DLLA85). LA-content was raised from 70% 
to 85%. Release profile (Figure 24) looks very similar, but the release rate is slightly 
higher than in PEG-P(CL30-DLLA70). With solid samples, measurements had to end 
before 2 months were past because fast degradation. Samples degraded in similar way 
than PEG-P(CL30-DLLA70) containing dexamethasone samples.  
From Figure 25 and Figure 26 is possible to compare measured results of dexame-
thasone samples while cumulative release (%) is shown as function of time. Fitting is 
done using measured initial values of dexamethasone. 
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Figure 25. Cumulative release of DEX from P(CL30-LLA70 and PEG-(CL30-LLA70) 
where p is used to mark porous samples, D means that sample includes dexamethasone, 
and number after D is theoretical drug content. 
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Figure 26. Cumulative release of DEX from PEG- P(CL30-DLLA70 and PEG-(CL15-
DLLA85) where p is used to mark porous samples, D means that sample includes dexa-
methasone, and number after D is theoretical drug content. 
 
5.6 Drug release of ascorbic acid salt 
Release of AAs from polymers was very different than dexamethasone release from the 
same polymers. This was probably due to different properties like solubility of drugs. 
All measuring and calculating was done in similar way than for dexamethasone contain-
ing samples. Cumulative ascorbic acid salt release from materials of P(CL30-LLA70), 
PEG-P(CL30-LLA70), PEG-P(CL30-DLLA70) and PEG-P(CL15-DLLA85) are pre-
sented in Figure 27, Figure 28, Figure 29 and Figure 30 respectively. Release curves 
are presented with error bars that are equal to calculated standard deviations.  
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Figure 27. Cumulative AAs release from P(CL30-LLA70) where p is used to mark po-
rous samples, A means that sample includes ascorbic acid salt, and number after A is 
theoretical drug content. 
In Figure 27 drug release from commercially available material is presented. Release 
profiles differ from others seen in this work. There are different phases in the release. At 
this point it would be useful to know better degradation behavior of P(CL30-LLA70). 
For solid samples, the release started from burst following a lag period. For higher AAs 
content drug, there was some release during the “lag period”. Faster release starts ap-
proximately at 20 day timepoint and for 4-wt% samples fast release starts approximately 
30 day timepoint. Burst effect is seen with all combinations. It looks that it is propor-
tional to the drug content. Burst is higher with porous samples compared to solid ones. 
This is probably due to the fact that the drug has easier path to solution due to higher 
surface area.  
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Figure 28. Cumulative AAs release from PEG-P(CL30-LLA70) where p is used to mark 
porous samples, A means that sample includes ascorbic acid salt, and number after A is 
theoretical drug content. 
It seems that adding PEG into the polymer backbone changed the release profile to 
obeying mostly first order kinetics. This was the material that was thought to react 
somehow with the drug during processing. Cumulative release curves are found from 
Figure 28 for PEG-P(CL30-LLA70). Burst effect is relatively high also here especially 
with porous samples. Again, it looks like drug content is proportional to burst effect. 
Almost all drug is released form 8-wt% samples during first days.  
When L-lactide was changed to DL-lactide (Figure 29), changes were seen in the re-
lease profile. With these amorphous materials, the release test had to be ended when 
samples were too degraded and measurements would not been reliable anymore. From 
solid samples, the release was almost negligible before material degraded. With porous 
samples, almost all drug was released rapidly.  
When LA/CL ratio is increased from 70/30 to 85/15 (Figure 30), profiles are really 
similar. However it looks like increasing LA-content increases release rates slightly. 
Burst release however looks slightly smaller. 
Both materials, PEG-P(CL30-DLLA70) and PEG-P(CL15-DLLA85) was kept in 
hydrolysis one week longer than same ones including dexamethasone. The different 
nature of drug was probably reason why DEX-samples degraded faster.  
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Figure 29. Cumulative AAs release from PEG-P(CL30-DLLA70) where p is used to 
mark porous samples, A means that sample includes ascorbic acid salt, and number 
after A is theoretical drug content. 
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Figure 30. Cumulative AAs release from PEG-P(CL15-DLLA85) where p is used to 
mark porous samples, A means that sample includes ascorbic acid salt, and number 
after A is theoretical drug content. 
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Figure 31. Cumulative release of AAS from P(CL30-LLA70) and PEG-P(CL30-LLA70) 
where p is used to mark porous samples, A means that sample includes ascorbic acid 
salt, and number after A is theoretical drug content. 
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Figure 32. Cumulative release of AAS from PEG-P(CL30-DLLA70).and PEG-P(CL15-
DLLA85) where p is used to mark porous samples, A means that sample includes ascor-
bic acid salt, and number after A is theoretical drug content. 
In Figure 31 and Figure 32 release profiles were scaled to maximum drug amount 
(100%). Maximum values are based on results from initial drug content measurements. 
Patterns looks more clear in these figures. With commercial samples it is interesting to 
notice that release after burst and lag phase starts more than a week later in 4-wt sam-
ples. Concentration gradient is bigger with higher drug content, but the drug may have 
effected to whole release system in a way, that was seen in earlier start of drug release. 
For example present drug may change the system to be more hydrophilic. 
Burst release was present with all AAs samples and was relatively high. With com-
mercial samples, a lag period was seen after burst. Yoon et al. (2003) suggested in their 
work that lag after burst release of drug was possibly caused by temporal shortage of 
drug for diffusion. Burst also increased while drug contents were increased. Similar was 
observed by Grinberg et al. (2010) in their study. It was suggested that higher force of 
diffusion caused higher burst at beginning.  
Zhang et al. (2004) prepared PEG-b-P(CL-co-LLA) nanoparticles with Camptothe-
cin derivative, a poorly water soluble cancer drug. It was suggested that fast release was 
due to molecularly dispersed drug and because of low Tg of used polymers. Low Tg was 
considered to make permeability of drug better than in glassy matrix.   
In study of Hu et al. (2003) also polymerized nanosized particles of lactide and ca-
prolactone in presence of ethylene glycol. Chemical composition of particles had key 
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role in controlling of drug Nimodipine release. Size of used PEG-block was varied from 
1000 g/mol to 20000 g/mol. Higher PEG-content led to higher release rate. 
 
5.7 Differential scanning calorimetry 
Results of DSC scans are shown in Table 8. Tgs were analyzed from second heating to 
make sure that samples had same thermal histories. Tms were analyzed from the first 
heating cycle. It is interesting notice that no melting peak can be found for P(CL30-
LLA70) which was expected to have some crystallinity in structure. Absence of crystal-
linity is probably because of fast cooling during processing.  
It seems that with all materials, blending dexamethasone causes and increase in 
glass transition temperatures. And it looks like increase of drug is consistent with blend-
ed drug content. Because drug changes the glass transition, it probably has good interac-
tion with polymers. PEG-P(CL15-DLLA85) makes an exception. For pure material Tg 
was 28.57 °C and for 4-wt% dexamethasone samples it decreased to 28.14 °C but with 
8-wt% samples it increases to 30.92 °C.  
For ascorbic acid, effect is not that clear. Glass transition temperatures increases 
with samples of P(CL30-LLA70) and PEG-P(CL15-DLLA85), but decreases for PEG-
P(CL30-LLA70) and remains almost at same level for PEG-P(CL30-DLLA70). When 
drug does not change glass transition temperature, it probably does not have good inter-
action with polymer matrix (Karjalainen et al. 2000). However decrease of glass transi-
tion temperature is usually connected to plastizising effect of drug (Yoon et al. 2003; 
Velasco et al. 2010). 
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Table 8. Results of DSC. For polymers without drug n=3 and polymers with drug n=5. 
A means ascorbic acid salt, D means dexamethasone and numbers 4 and 8 theoretical 
drug contents.  
Sample Tg (°C) sd Tm (°C) sd 
P(CL30-LLA70) 23.07    
      A4 23.20 0.43   
      A8 23.26 0.72   
      D4 24.76 0.31   
      D8 24.27 0.42   
PEG-P(CL30-LLA70) 19.96  144.91  
      A4 19.39 0.28 145.49 0.26 
      A8 17.98 0.78 145.27 0.22 
      D4 20.91 0.89 144.41 0.18 
      D8 21.27 0.78 144.18 0.57 
PEG-P(CL30-DLLA70) 35.24    
      A4 35.26 0.68   
      A8 35.15 0.35   
      D4 36.14 0.57   
      D8 36.50 0.34   
PEG-P(CL15-DLLA85) 28.57    
      A4 30.60 0.52   
      A8 30.53 1.72   
      D4 28.14 0.51   
      D8 30.92 2.94   
 
Melting peaks were possible to find only for PEG-P(CL30-LLA70) samples. For AAs 
containing samples, melting temperatures increased while dexamethasone containing 
samples had opposite effect.  
For all analyzed results, the standard deviations were somewhat high even five par-
allel samples were used. Although, polymers were purified only once and it was noticed 
that AAs did not blend very well with used polymers.  
As it was mentioned before, caprolactone has been favored in drug release applica-
tions due to its good permeability to drugs which is caused by low glass transition tem-
perature. Measured results showed that PEG-P(CL30-LLA70) had lowest Tg. Glass 
transition of pure polymer without any drug was 19.96 °C. Tg of P(CL30-LLA70) was 
23.07 °C, PEG-P(CL30-DLLA70) had 35.24 and PEG-P(CL15-DLLA85) had 28.57 °C. 
Last two polymers have relatively high glass transitions, especially PEG-P(CL30-
DLLA70) which is relatively close to physiological temperature. These two polymers 
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had the lowest release rates with solid samples. Permeation of drugs was probably 
somewhat poor. 
5.8 Thermogravimetric analysis 
Thermogravimetric analysis was done once for each drug-polymer combinations (n=1). 
In Figure 33  TGA curves for 8-wt% dexamethasone containing samples and in figure 
Figure 34 same except for ascorbic acid salt are presented. In both cases, black line is 
for P(CL30-LLA70), blue for PEG-P(CL30-LLA70), green for PEG-P(CL30-DLLA70) 
and red for PEG-P(CL15-DLLA85) samples.  
 
 
Figure 33. TGA curves for 8-wt% containing DEX samples. Black line is for P(CL30-
LLA70), blue for PEG-P(CL30-LLA70), green for PEG-P(CL30-DLLA70) and red for 
PEG-P(CL15-DLLA85). 
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Figure 34. TGA curves for 8-wt% containing AAs samples. Black line is for P(CL30-
LLA70), blue for PEG-P(CL30-LLA70), green for PEG-P(CL30-DLLA70) and red for 
PEG-P(CL15-DLLA85). 
 
As it can be seen from figures, mass starts to decrease earlier from AAs samples than 
from DEX samples. AAs curves does not reach 0-wt% at end of measurement. It was 
noticed that there were some residues left in sample container. 
5.9 microCT 
2D images of each kind of samples are presented in Table 9 and Table 10. In ascorbic 
acid containing samples, it is possible to see white areas which cannot be found from 
dexamethasone containing samples. These are probably drug that is in dispersed form. It 
was already known that the drug did not blend very well with used polymers. There are 
also more white areas in samples containing higher amount of drug. Samples looks very 
porous except PEG-P(CL30-LLA70) samples. 
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Table 9. 2D µCT-images of porous samples containing ascorbic acid salt. Length of scale bar is 
1mm and it is found from left bottom corner. Unfortunately those are not shown very well in 
small images. 
Ascorbic 
acid salt 
4-wt% 8-wt% 
P(CL30-
LLA70) 
  
PEG-
P(CL30-
LLA70) 
  
PEG-
P(CL30-
DLLA70) 
  
PEG-
P(CL15-
DLLA85) 
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Table 10. 2d µCT-images of porous samples containing dexamethasone. Length of scale 
bar is 1mm and it is found from left bottom corner. Unfortunately those are not shown very well 
in small images. 
Dexame-
thasone 
4-wt% 8-wt% 
P(CL30-
LLA70) 
  
PEG-
P(CL30-
LLA70) 
  
PEG-
P(CL30-
DLLA70) 
  
PEG-
P(CL15-
DLLA85) 
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Table 11. 3D µCT-images of different porous materials having 4-wt% ascorbic acid 
salt. Length of scale bar is 1mm and it is found from left bottom corner. Unfortunately those are 
not shown very well in small images. 
P(CL30-LLA70) 
 
PEG-P(CL30-LLA70) 
 
PEG-P(CL30-DLLA70) 
 
PEG-P(CL15-DLLA85) 
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Pores became more visible in 3D images (Table 11). Images shown are from 4-wt% 
ascorbic acid salt containing samples. It looks like PEG-P(CL30-DLLA70) has largest 
pores and it would have also biggest porosity. Pores may have good interconnectivity. 
On the contrary, in PEG-P(CL30-LLA70) samples very small pores are seen. It was also 
possible to do some quantitative analysis. Some results are summarized in Table 12. 
 
Table 12. Analysis done based on CT-images. A means ascorbic acid salt, D means 
dexamethasone and numbers 4 and 8 theoretical drug contents. 
Name Porosity 
(%) 
Void thick-
ness mean 
(µm) 
Void 
thickness 
std (µm) 
Area/Volume  
P(CL30-LLA70)     
      A4 62 153 62 0.0481 
      A8 60 171 73 0.0373 
      D4 65 219 110 0.0391 
      D8 66 204 90 0.0423 
PEG-P(CL30-LLA70)     
      A4 31 58 57 0.0511 
      A8 21 31 16 0.0402 
      D4 23 53 56 0.0353 
      D8 19 43 43 0.0335 
PEG-P(CL30-DLLA70)     
      A4 61 245 147 0.0324 
      A8 72 313 166 0.0378 
      D4 57 166 87 0.0402 
      D8 57 176 99 0.0369 
PEG-P(CL15-DLLA85)     
      A4 64 151 73 0.0557 
      A8 60 127 67 0.0535 
      D4 61 114 61 0.0603 
      D8 61 118 58 0.0586 
 
General porosity, pore size with standard deviation and area/volume were analyzed for 
each sample. Porosities were around 60% in general except for PEG-P(CL30-LLA70) it 
varied between 19-31%. Mean pore size varied more. For PEG-P(CL30-DLLA70) had 
largest (166-313µm) pores which was already possible to see from CT-images. PEG-
P(CL30-LLA70) had smallest pores (31-58µm).  
Low porosity of PEG-P(CL30-LLA70) was somewhat surprising because it had rel-
atively low i.v. and molecular weight compared to other polymers used. However crys-
tallinity is suggested to have effect how well pores are formed due to morphological 
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effects to CO2 solubility to polymer (Davies et al. 2008). Sheridan et al. (2000) Prepared 
porous PLGA scaffolds using high pressure CO2. In their work, samples having high 
molecular weights did not have high porosity of same material with different molecular 
weights. It was suggested that longer polymer chains had more resistant against expan-
sion than shorter ones had. In their work, the amorphous PLGA polymers foamed better 
than homopolymers of each monomer. It was suggested that CO2 had better dissolution 
into amorphous regions. (Sheridan et al. 2000)  PEG-P(CL30-LLA70) was only poly-
mer that had some crystallinity when samples were processed and can possibly explain 
why other polymers gained better porosity.    
Area/volume ratio varied approximately 0.0324 to 0.0603. No clear trends are seen 
at this point.      
5.10 Effect of drug properties 
It seems that properties of drugs had the most dominant effect on release profiles with 
used polymers. Used drugs were very different in nature and it was seen in release be-
havior. Ascorbic acid salt is very well-soluble in water whereas dexamethasone has very 
low solubility. On contrary, AAs is not soluble in many other solvents. It was noticed 
already in blending that AAs did not blend well in the polymers used. Also standard 
deviations in measurements of initial drug contents and actual drug release measure-
ments were relatively high which indicated that drug was not homogenously dissolved 
in polymer. Also µCT-images showed that AAs was dispersed in polymer since white 
areas were clearly seen in pictures. Similar white areas were not seen in dexamethasone 
containing samples. Standard deviations from dexamethasone samples were much 
smaller in initial drug content measurements and in actual drug release measurements. 
Release patterns were very different. AAs released either very fast or release was 
almost negligible until samples degraded. AAs probably had very weak interaction with 
matrix polymers. 
Similar kind of conclusions was done by Dorj et al. (2014) by preparing porous 
PLLA scaffold for drug release with porosity of approximately 70%. Hydrophilic anion-
ic Ampicillin released really fast. Approximately 85% was released during first week. It 
was suggested that drug and polymers had weak chemical interaction. However another 
drug used, Cytochome C came out in very different way. After burst release, cytocine C 
was released in sustained way up to 28 days. Release remained in steady state after 
burst. Cyticine C has positive charge and is expected have interactions with polymer. 
For both drugs, nonporous samples were also prepared. Since drugs were loaded into 
scaffolds by soaking samples in drug loaded solution, loading into nonporous samples 
were relatively poor and release was not steady.  (Dorj et al. 2014)  
It was also suggested that differences in release profiles from same material may be 
due to differences in drugs functional groups that can react differently with hydrogen 
bonds of polyester (Jelonek et al. 2013). Our drugs has quite different structures but size 
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does not differ much. Dexamethasone has molecular weight of approximately 392 g/mol 
and AAs 322 g/mol. 
Lee et al. (2009) studied well water soluble α-lipoic acid release from PEG-P(CL60-
DLLA40). Drug was blended homogenously in copolymer including PEG, but distrib-
uted on the surface of polymer samples without PEG. Used PEG were 350 g/mol. After 
24 hours, 90 % of drug was released from samples without PEG and 50 % from samples 
with PEG. In our study, AAs were poorly soluble to used materials and when PEG was 
incorporated to structure, release became faster. Here, it can be concluded that even 
solubility of drug plays important role and can be dominant factor affecting the release 
of drug. 
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6 CONCLUSIONS 
In vitro drug release test series was done to four different copolymers. Lactide and ca-
prolactone were synthesized in presence of ethylene glycol to produce block structure 
where PEG is in middle of chain. Commercial P(CL30-LLA70) was used to compare 
results of experimental materials. Characterization like differential scanning calorime-
try, thermogravimetric analysis, capillaryviscometric analysis and size-exclusion chro-
matography was used materials to understanding better behavior of drug-material rela-
tionship. Samples were prepared using two different drugs, two drug contents (4-wt% 
and 8-wt% in feed) and porous and nonporous samples. 
Main interest was in the drug release. Drug release was monitored using UV/VIS-
spectrophotometer. Many factors affecting to release behavior were found. In general 
PEG incorporation into backbone increased release rates for all materials and for AAs 
samples, it changed release profiles too. It was known that PEG increases hydrophilici-
ty, which makes water absorption to polymer easier and affects the degradation kinetics 
by increasing the release rate.  
By changing type of lactide, from L-lactide to DL-lactide, release from solid sam-
ples became very minimal, for most samples, negligible. These amorphous materials 
changed release rates when they were processed with sCO2. Dexamethasone was re-
leased before samples were too degraded for measuring and AAs was released in very 
fast way. 
When DL-content was increased, the release profiles remained similar, but release 
rates increase slightly with both drugs. Content of drugs did not affect much to release 
profile in general, but it was possible to tailor release rates.  
Most of all, properties of drugs had a great effect on the release. AAs had relatively 
weak interaction with matrix polymers, while dexamethasone did not show any signs of 
being in dispersed form. With dexamethasone, sustained nearly zero-order kinetics was 
possible to achieve for over 120 days for porous semi-crystalline polymers used. Pro-
cessing samples with super critical CO2 increased release rates of all samples. 
Suggestions to future work would be doing degradation test series that would help 
understanding the release behavior of used materials better. Even though, there are liter-
ature found about degradation of similar materials, it was noticed that drug can effect 
also to whole implant and degradation. More than one week delay at beginning of drug 
release was seen in commercial AAs samples with different drug contents. Also release 
test series were finished one week earlier to some samples due to faster degradation. 
Changes of materials properties, especially changes in structure would be interesting to 
monitor and compare how well these changes correlate with changes in release profiles. 
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Additionally, more characterization to understand better the complex relationships of 
factors affecting the release is necessary.  
These materials clearly have great potential in drug release applications. Especially 
dexamethasone could potentially be used in applications that needs long term drug re-
lease. This was a pilot study and there was not made effort to consider whether results 
were therapeutic doses of not. Also samples were chosen not to be sterilized before test 
series. Testing sterilized samples would be highly recommended since it is known to 
affect material properties.  
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APPENDIX A: RELEASE OF DEXAMETHASONE 
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APPENDIX B: RELEASE OF ASCORBIC ACID SALT 
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